Earn 1.5 RAC Credits
The Jumpstart Our Business Startups (JOBS) Act significantly impacts small and mid-market life science firms by providing new fundraising options and easing the burden of complying with securities laws. Find out what later-stage private companies that may be considering their options for public fundraising need to know about the JOBS Act.
Join us for a 90-minute Webinar along with financial and legal experts in this field -- Daniel B. Dubin, M.D. Vice Chairman of Leerink Swann LLC , William C. Hicks, Member in the Corporate/Securities Section of Mintz Levin and Jack Hogoboom, Member and co-chair of the Life Sciences Group at Lowenstein Sandler. This interactive program will focus on how the JOBS Act facilitates traditional IPOs, encourages modest sized IPOs by entrepreneurial companies, provides new flexibility for alternative going public processes, and will provide a revitalized Regulation “A” pathway by allowing private companies to raise up to $50 million in an unregistered public offering of unrestricted shares. Speakers will also discuss how the JOBS Act will ease the reporting requirements for small companies once they go public and impact current financing alternatives for small and mid-market public life sciences companies.
Key Takeaways for Participants:
• Learn how the IPO on ramp provisions of the JOBS Act will facilitate traditional IPOs for entrepreneurial life sciences firms and ease the burden of public company life
• Understand alternative initial public offering paths, and the impact of the JOBS Act on the spectrum of creative structuring alternatives
• Be introduced to $50 million Regulation A offerings, how they may be revived by the JOBS Act, and where they will fit in the menu of structuring solutions
• Understand how changes to general solicitation rules will impact private and public offerings and strategic planning for financing alternatives
• Update on confidentially marketed public offerings; registered directs and PIPEs, and the potential impact of doctrinal changes under the JOBS Act
Don’t miss out on the opportunity to learn how private companies looking to take the next step should strategically approach the spectrum of deal structuring solutions.
Who Should Attend:
• CEOs and CFOs of life sciences companies
• Venture Capital and Private Equity Firms with late stage portfolio companies
• Investors
• Finance staff
• Investor relations staff
• General counsel and corporate counsel
Your Experts:
Daniel B. Dubin, M.D. is Vice Chairman of Leerink Swann LLC. Daniel B. Dubin has been an advisor to institutional investors and corporate life sciences clients since 1996. He is a member of Leerink Swann's Management Committee and Chair of its Capital Commitment Committee as well as a founder of MEDACorp. Dr. Dubin has assisted emerging growth companies in raising nearly $4 billion of capital and has led many of the higher profile private placements and alternative IPO transactions in the life sciences sector. He was an instructor in Dermatology at Harvard Medical School and served as the Ambulatory Medical Director of the Dermatology Division at the Brigham and Women's Hospital. Dr. Dubin is a graduate of Dartmouth College and Harvard Medical School and completed both an internship in internal medicine and a residency in Dermatology at Massachusetts General Hospital. He serves as a director of Leerink Swann and as an advisor to SKS Ocular and Living Proof.
William C. Hicks is a Member in Mintz Levin’s New York office. Bill has extensive experience representing placement agents and underwriters in structuring and executing initial public offerings, alternative public offerings, including reverse mergers, Form 10/Resale S-1 deals and confidentially marketed IPOs, Confidentially Marketed Public Offerings (CMPOs), registered directs, PIPEs and private placements. Bill represents venture capital firms and private equity firms in customized investments in public companies, including structured PIPEs and registered directs, in OTC and exchange listed companies. Bill also represents public companies in public and private financings, SEC compliance, corporate governance and general counseling. Bill has extensive experience representing buyers and sellers in M&A transactions, including public company deals, private company deals and spin-offs.
Jack Hogoboom is a founding member of the Lowenstein Sandler Specialty Finance Group and is co-chair of the Life Sciences group. Jack specializes in representing clients in the life sciences and other industries in mergers and acquisitions, public and private securities offerings, private equity investments and general corporate and securities law.Jack is listed among The Best Lawyers in America in the 2007-2012 editions of the publication in both the corporate law and securities law categories. Jack earned his J.D. from University of Pennsylvania School of Law and is admitted to practice in New Jersey and New York.
Mari Serebrov, Moderator
As the Washington editor for BioWorld Today, Mari Serebrov covers key business and regulatory news related to the biopharmaceutical industry. Mari is a senior-level writer with 25+ years of diversified experience in publishing for academic, business-to-business and consumer audiences. She joined the BioWorld team in 2011.
This cour
se has been pre-approved by RAPS as eligible for up to 1.5 credits towards a participant's RAC recertification upon full completion without requiring additional paper documentation. Details for RAPS recertification can be found by visiting http://www.raps.org/certification/recertification.aspx
Thompson Interactive is a Regulatory Affairs Professionals Society (RAPS) RA Professional Development Portal provider. Thompson Interactive is committed to enhancing the ongoing professional development of regulatory affairs professionals and other stakeholders through appropriate regulatory affairs learning activities and programs Thompson Interactive has agreed to follow RAPS-established operational and educational criteria.
